FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2280407992> ?p ?o ?g. }

• W2280407992 endingPage "62938" @default.
• W2280407992 startingPage "62925" @default.
• W2280407992 abstract "// I-Ling Hsu 1 , Cheng-Yang Chou 2 , Yi-Ying Wu 3 , Jia-En Wu 1 , Chen-Hsien Liang 1 , Yao-Tsung Tsai 1 , Jhen-Yu Ke 4 , Yuh-Ling Chen 1, 4 , Keng-Fu Hsu 2, 3 and Tse-Ming Hong 1, 3 1 Institute of Basic Medical Sciences, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 2 Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 3 Graduate Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 4 Institute of Oral Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan Correspondence to: Tse-Ming Hong, email: tmhong@mail.ncku.edu.tw Yuh-Ling Chen, email: yuhling@mail.ncku.edu.tw Keng-Fu Hsu, email: d5580@mail.ncku.edu.tw Keywords: FXYD2, ovarian clear cell carcinoma, Na + /K + -ATPase, cardiac glycoside Received: June 29, 2015     Accepted: January 17, 2016     Published: February 19, 2016 ABSTRACT Ovarian clear cell carcinoma (OCCC) is an aggressive neoplasm with a high recurrence rate that frequently develops resistance to platinum-based chemotherapy. There are few prognostic biomarkers or targeted therapies exist for patients with OCCC. Here, we identified that FXYD2, the modulating subunit of Na + /K + -ATPases, was highly and specifically expressed in clinical OCCC tissues. The expression levels of FXYD2 were significantly higher in advanced-stage of OCCC and positively correlated with patients’ prognoses. Silencing of FXYD2 expression in OCCC cells inhibited Na + /K + -ATPase enzyme activity and suppressed tumor growth via induction of autophagy-mediated cell death. We found that high FXYD2 expression in OCCC was transcriptionally regulated by the transcriptional factor HNF1B. Furthermore, up-regulation of FXYD2 expression significantly increased the sensitivity of OCCC cells to cardiac glycosides, the Na + /K + -ATPase inhibitors. Two cardiac glycosides, digoxin and digitoxin, had a great therapeutic efficacy in OCCC cells in vitro and in vivo . Taken together, our results demonstrate that FXYD2 is functionally upregulated in OCCC and may serve as a promising prognostic biomarker and therapeutic target of cardiac glycosides in OCCC." @default.
• W2280407992 created "2016-06-24" @default.
• W2280407992 creator A5000313540 @default.
• W2280407992 creator A5002799334 @default.
• W2280407992 creator A5017817869 @default.
• W2280407992 creator A5023128769 @default.
• W2280407992 creator A5040631280 @default.
• W2280407992 creator A5056283282 @default.
• W2280407992 creator A5057302814 @default.
• W2280407992 creator A5069509004 @default.
• W2280407992 creator A5071069907 @default.
• W2280407992 creator A5086128788 @default.
• W2280407992 date "2016-02-19" @default.
• W2280407992 modified "2023-09-27" @default.
• W2280407992 title "Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma" @default.
• W2280407992 cites W1559932979 @default.
• W2280407992 cites W1791183955 @default.
• W2280407992 cites W1853680291 @default.
• W2280407992 cites W1970151280 @default.
• W2280407992 cites W1970221409 @default.
• W2280407992 cites W1976531450 @default.
• W2280407992 cites W1981831739 @default.
• W2280407992 cites W1986085836 @default.
• W2280407992 cites W1993974831 @default.
• W2280407992 cites W2001560286 @default.
• W2280407992 cites W2001877789 @default.
• W2280407992 cites W2011811704 @default.
• W2280407992 cites W2013641545 @default.
• W2280407992 cites W2034846334 @default.
• W2280407992 cites W2037565051 @default.
• W2280407992 cites W2041328165 @default.
• W2280407992 cites W2042202715 @default.
• W2280407992 cites W2042209114 @default.
• W2280407992 cites W2048947295 @default.
• W2280407992 cites W2051917121 @default.
• W2280407992 cites W2052235980 @default.
• W2280407992 cites W2053201029 @default.
• W2280407992 cites W2062254269 @default.
• W2280407992 cites W2066948394 @default.
• W2280407992 cites W2067841857 @default.
• W2280407992 cites W2069529251 @default.
• W2280407992 cites W2070358111 @default.
• W2280407992 cites W2081318222 @default.
• W2280407992 cites W2083395646 @default.
• W2280407992 cites W2097293117 @default.
• W2280407992 cites W2100194579 @default.
• W2280407992 cites W2116870857 @default.
• W2280407992 cites W2119379108 @default.
• W2280407992 cites W2127152090 @default.
• W2280407992 cites W2138274847 @default.
• W2280407992 cites W2141112224 @default.
• W2280407992 cites W2142048790 @default.
• W2280407992 cites W2169961966 @default.
• W2280407992 cites W2172287945 @default.
• W2280407992 cites W2219978888 @default.
• W2280407992 cites W2433882967 @default.
• W2280407992 doi "https://doi.org/10.18632/oncotarget.7497" @default.
• W2280407992 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5325337" @default.
• W2280407992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26910837" @default.
• W2280407992 hasPublicationYear "2016" @default.
• W2280407992 type Work @default.
• W2280407992 sameAs 2280407992 @default.
• W2280407992 citedByCount "25" @default.
• W2280407992 countsByYear W22804079922016 @default.
• W2280407992 countsByYear W22804079922018 @default.
• W2280407992 countsByYear W22804079922019 @default.
• W2280407992 countsByYear W22804079922020 @default.
• W2280407992 countsByYear W22804079922021 @default.
• W2280407992 countsByYear W22804079922022 @default.
• W2280407992 countsByYear W22804079922023 @default.
• W2280407992 crossrefType "journal-article" @default.
• W2280407992 hasAuthorship W2280407992A5000313540 @default.
• W2280407992 hasAuthorship W2280407992A5002799334 @default.
• W2280407992 hasAuthorship W2280407992A5017817869 @default.
• W2280407992 hasAuthorship W2280407992A5023128769 @default.
• W2280407992 hasAuthorship W2280407992A5040631280 @default.
• W2280407992 hasAuthorship W2280407992A5056283282 @default.
• W2280407992 hasAuthorship W2280407992A5057302814 @default.
• W2280407992 hasAuthorship W2280407992A5069509004 @default.
• W2280407992 hasAuthorship W2280407992A5071069907 @default.
• W2280407992 hasAuthorship W2280407992A5086128788 @default.
• W2280407992 hasBestOaLocation W22804079921 @default.
• W2280407992 hasConcept C126322002 @default.
• W2280407992 hasConcept C143998085 @default.
• W2280407992 hasConcept C2777546739 @default.
• W2280407992 hasConcept C2781199814 @default.
• W2280407992 hasConcept C3017595490 @default.
• W2280407992 hasConcept C71924100 @default.
• W2280407992 hasConceptScore W2280407992C126322002 @default.
• W2280407992 hasConceptScore W2280407992C143998085 @default.
• W2280407992 hasConceptScore W2280407992C2777546739 @default.
• W2280407992 hasConceptScore W2280407992C2781199814 @default.
• W2280407992 hasConceptScore W2280407992C3017595490 @default.
• W2280407992 hasConceptScore W2280407992C71924100 @default.
• W2280407992 hasIssue "39" @default.
• W2280407992 hasLocation W22804079921 @default.
• W2280407992 hasLocation W22804079922 @default.
• W2280407992 hasLocation W22804079923 @default.

• next